BriaCell is a Los Angeles based breast cancer immunotherapy biotech which has developed a patented whole-cell vaccine, cancer immunotherapy technology called the "BriaVax" vaccine. The vaccine has demonstrated highly encouraging Phase-I safety and efficacy data in patients with advanced breast cancers.
Although the company has demonstrated remarkable results in its early clinical trials, the seasoned team is focused on aggressively advancing its vaccine by building upon its success and launching into an expanded clinical trial to include a larger patient base while simultaneously carrying out extensive scientific R&D on its data.
The Company is planning to advance its cancer immunotherapy technology in an approved FDA Phase I/II clinical trial with up to 24 breast cancer patients with advanced stages of solid tumors. By doing this, the Company hopes to further demonstrate a strong basis of data behind its potentially life-altering vaccine.
While the current focus of the company remains late-staged breast cancers, the Company recognizes that its concepts and technologies may have the potential to be applied to other similarly natured solid cancers as well. The FDA has recognized this potential and the approved protocol has provision to allow testing the vaccine in selected patients with other cancers as well, including prostate, ovarian, pancreas, lung and bladder cancers among others.
Seasoned team determined to build upon its remarkable results